Application of Validation Principles To The Training Quality System - Part 3: Trainers

When training content is designed and developed, desired trainer skills for successful training delivery are identified.  These include personal background and experience; training content technical expertise; and human factors and communication skills appropriate for the intended training.  Trainers meeting these requirements are developed and are ultimately qualified for training.  Specific individual topics addressed include User Requirements Specifications (URS), Functional Requirements Specifications (FRS) and Technical Requirements Specifications (TRS), trainer recruiting and...

This content is only available to IVT members.
Get help maintaining your knowledge in GMP - Corrective & Preventative Action (CAPA). Read More!

If you are already a member and you do not have access to this article, upgrade your membership.
Need help? Read our FAQs.




Product Added Successfully

This product has been added to your account and you can access it from your dashboard. As a member, you are entitled to a total of 0 products.

Do you want access to more of our products? Upgrade your membership now!

Your Product count is over the limit

Do you want access to more of our products? Upgrade your membership now!

Product added to cart successfully.

You can continue shopping or proceed to checkout.

This webinar will discuss the fundamentals of effective and US Food and Drug Administration-compliant process validation. The background to FDA's Process Validation: General Principles and Practices will be discussed, and the requirements will be analyzed.

Evaluating Data for an Annual Product Review

The Annual Product review (APR) is one of the most critical and useful tools that a company has in its quality arsenal. If done properly, it will be a decision making tool for validation, production, quality investigations, process optimization, training, and quality systems development. These are just a few of the uses, however, as this paper will endeavor to explain, the uses are unlimited. This paper will discuss the process from both a quality and regulatory perspective, and explain how it is linked into the quality and production departments of a firm.

This content is only available to IVT members.
Get help maintaining your knowledge in GMP - Documentation & Records and Reports. Read More!

If you are already a member and you do not have access to this article, upgrade your membership.
Need help? Read our FAQs.




GXP Talk: Question 70

“GXP Talk ” provides a forum for compliance practitioners to address issues identified by the readers of the Journal of GXP Compliance. What are the Regulatory Requirement and Expectations for Process Improvements in the Pharmaceutical Industry?

This content is only available to IVT members.
Get help maintaining your knowledge in Regulation. Read More!

If you are already a member and you do not have access to this article, upgrade your membership.
Need help? Read our FAQs.




Assessing Process Hold Times for Microbial Risks: Bioburden and Endotoxin

This paper has discusses the implications of the process hold times on microbial growth during pharmaceutical manufacturing. Microbiological risk exists -- especially with biological products. If microbial contamination occurs where microorganisms enter a product in sufficient numbers and if the process hold time is long enough, the process hold time may be problematic.

This content is only available to IVT members.
Get help maintaining your knowledge in Cleaning Validation. Read More!

If you are already a member and you do not have access to this article, upgrade your membership.
Need help? Read our FAQs.




An Investment in Knowledge Pays the Best Interest—Are You Leveraging Your Investment in Your CTDs by Using the Knowledge?

This study set out to establish the typical sources of product and process knowledge currently used to support decision-making for post-approval changes and continuous improvement strategies.  It explores whether it is standard practice within industry to utilise the prior knowledge available within the CTD to support day-to-day lifecycle management.  It also explores the potential benefits of leveraging the Quality Overall Summary (QoS), Module 2 of the CTD, to support ongoing management of knowledge throughout the commercial manufacturing and post-market operations. 

This content is only available to IVT members.
Get help maintaining your knowledge in GMP. Read More!

If you are already a member and you do not have access to this article, upgrade your membership.
Need help? Read our FAQs.




Data Integrity Issues in Pharmaceutical Companies: Part 2

In recent years there has been a significant increase in the number and types of data integrity issues that have been cited in regulatory inspections by both USA and European (especially MHRA) investigators. This increase has led to the FDA establishing the types of issues that should be considered red flags triggering a more intensive investigation. One of the areas prone to data integrity issues is the pharmaceutical laboratory. This article discusses data integrity issues and how they can be of concern in the laboratory.

This content is only available to IVT members.
Get help maintaining your knowledge in Documentation. Read More!

If you are already a member and you do not have access to this article, upgrade your membership.
Need help? Read our FAQs.




Mastering Regulatory Compliance: Cybersecurity and Green / Lean Validation Strategies

Peer Reviewed: Green Validation